Editas Medicine Inc (NASDAQ: EDIT) has reported a loss for its fourth fiscal quarter (ending December 31) of $-0.23 versus a loss $-0.88 for the same period a year ago. This result exceeded the consensus estimate of $-0.48 by $0.25. For the latest four quarters through December 31, E.P.S. were $-2.02 versus $-3.21 for the same period a year ago.
Recent Price Action
On 2/28/24, Editas Medicine Inc (NASDAQ: EDIT) stock enjoyed a major increase of 24.9%, closing at $11.07. Moreover, this advance was accompanied by exceptionally high trading volume at 423% of normal. The stock has performed in line with the market over the last nine months and has risen 39.2% during the last week.
Current PriceTarget Research Rating
EDIT is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Editas Medicine has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Editas Medicine has a neutral Power Rating of 47 but a poor Appreciation Score of 19, resulting in the Negative Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment